Ozanezumab

DB12891InvestigationalProtein Based Therapies

Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.

Mechanism: Pharmacologically active on Reticulon-4
Curator reviewed
Also known as: IMMUNOGLOBULIN G1, ANTI-(PROTEIN NOGO-A) (HUMAN-MUS MUSCULUS MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LIGHT CHAIN, DIMER
Code names: GSK-1223249

Resolves to

Compound

UNII123I05210WCAS1310680-64-8

Targets

Q9NQC3RTN4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ozanezumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account